LONG-TERM EFFECTS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS ON CORONARY HEART DISEASE IN PATIENTS WITH MULTIVESSEL STENOTIC CORONARY ARTERY ATHEROSCLEROSIS AND ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: POST-TRIAL ANALYSIS
UDC 616.127-005.8:616.13:615.361
DOI:
https://doi.org/10.31684/25418475-2023-2-15Keywords:
omega-3 fatty acids, docosahexaenoic acid, eicosapentaenoic acid, cardiovascular disease, triglycerides, low-density lipoprotein cholesterolAbstract
Introduction. Many studies have shown a clear association between certain dietary fats and mortality. However, data on specific dietary fats and mortality among patients with cardiometabolic disease remain equivocal. Low-density lipoprotein cholesterol is considered an important target for the prevention and treatment of atherosclerotic cardiovascular disease. However, many patients still have residual cardiovascular risks even if low-density lipoprotein cholesterol reaches target levels. Recent evidence suggests that elevated triglycerides or triglyceride-rich lipoprotein cholesterol are an important component of residual cardiovascular risk. Omega-3 fatty acids have been an effective treatment for the reduction of triglycerides. The objective of this study was to evaluate the association between long-term omega-3 fatty acid intake and prognosis in patients with coronary heart disease in the context of multivessel coronary disease after myocardial infarction. Materials and Methods. The authors conducted post-trial follow-up of patients 5 years after the 12-month study on the efficacy and safety of ω-3 PUFAs in a dose of 1000 mg/day in the course of coronary heart disease with multivessel coronary disease after myocardial infarction. In retrospect, all patients who previously participated in the study were divided into three groups: Group 1 - patients who did not receive ω-3-PUFAs during the main study (information was obtained for 111 patients), Group 2 - patients who received ω-3-PUFAs during the study but did not receive (or received episodically) ω-3-PUFA during 5 years after the study (information was obtained for 61 such patients) and patients who received the study drug during the study and continued taking it continuously, with interruptions of only 2 weeks, during 5 years after the study (information on 32 patients was obtained). Results and discussion. After discontinuation of ω-3 PUFA for 5 years, its clinical efficacy registered after 12 months of continuous use was completely leveled, while the positive effect achieved after 12 months of observation in the case of continuation of ω-3 PUFA during the next 5 years not only did not disappear, but also had a cumulative character (P <0,02-0,03). The importance of long-term, preferably lifelong, ω-3-PUFAs at a dose of 1000 mg was established in the cohort of patients in the study. Conclusions. The results of the present study suggest that ω-3 PUFAs in 1000 mg may be associated with a lower all-cause mortality in patients with coronary heart disease against the background of multivessel coronary lesions after myocardial infarction.
Downloads
References
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Маргарита Николаевна Синькова, Леонид Константинович Исаков, Максим Алексеевич Синьков, Екатерина Юрьевна Плотникова
This work is licensed under a Creative Commons Attribution 4.0 International License.